Sheba 2.0 - What we know
At least 20 patients enrolled.
3 patients responded during the P1 dose escalation stage and subsequently bridged to SCT.
At least 1 additional patient has responded during the P2 expansion (otherwise the study would have been terminated for futility).
That's at least 4 patients out of 20 (20% response rate).
"Anything above 10% would be a good response given the patients in the trial."
Ann: Letter to Shareholders, Notice of AGM & Proxy Form, page-34
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.105(6.14%) |
Mkt cap ! $309.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $862.1K | 467.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |